Amgen Inc., a large-cap biotech company, has a market cap of $154.9 billion and a strong cash position for growth. Its stock has declined but outperformed the S&P 500. Despite lackluster price action, Amgen’s Q2 earnings beat expectations. Analysts are optimistic about its future, giving it a “Moderate Buy” rating.

The company is focusing on developing solutions for high unmet medical needs and is set to release Phase 2 data for its weight-loss therapy. Despite regulatory challenges in the healthcare sector, Amgen is projected to have a solid long-term trajectory. Its main competitor, Bristol-Myers Squibb, has not performed as well in the past year.

Though facing challenges, Amgen’s management has raised fiscal 2025 guidance, expecting increased sales and adjusted EPS. Analysts are confident in the company’s future, with a mean price target of $315.26. Despite recent stock dips, Amgen’s strategic vision and operational strength continue to drive investor interest.

Read more at Yahoo Finance: Is Amgen Stock Underperforming the S&P 500?